Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Down 12.3% in March

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 6,400 shares, a drop of 12.3% from the February 28th total of 7,300 shares. Based on an average daily volume of 81,100 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

Enzon Pharmaceuticals Stock Performance

ENZN opened at $0.11 on Thursday. Enzon Pharmaceuticals has a fifty-two week low of $0.06 and a fifty-two week high of $0.24. The stock has a market cap of $7.96 million, a price-to-earnings ratio of 10.74 and a beta of 0.26. The firm’s fifty day moving average is $0.12 and its 200 day moving average is $0.12.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.